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Vascular endothelial growth factor (VEGF121) protects rats The hemolytic uremic syndrome (HUS), frequently
from renal infarction in thrombotic microangiopathy. associated with infection with verotoxin-producing Esch-
Background. Renal thrombotic microangiopathy, typified erichia coli, is an example of thrombotic microangiopa-by the hemolytic uremic syndrome, is associated with endothe-
thy (TMA) affecting the renal microvasculature. It islial cell injury in which the presence of cortical necrosis, exten-
characterized by acute renal failure, hemolytic anemia,sive glomerular involvement, and arterial occlusive lesions cor-
relates with a poor clinical outcome. We hypothesized that the and thrombocytopenia. It occurs predominantly in chil-
endothelial survival factor vascular endothelial growth factor dren, for whom it comprises one of the major causes of
(VEGF) may provide protection. acute renal failure, but it can also affect adults in whomMethod. Severe, necrotizing, thrombotic microangiopathy
a more severe clinical course often is observed [1, 2].was induced in rats by the renal artery perfusion of antiglomer-
Treatment has generally been only supportive, althoughular endothelial antibody, followed by the administration of
VEGF or vehicle, and renal injury was evaluated. plasma exchange has been used in uncontrolled studies.
Results. Control rats developed severe glomerular and tubu- While most patients have complete functional renal re-
lointerstitial injury with extensive renal necrosis. The adminis- covery, the mortality rate is estimated to be as high astration of VEGF significantly reduced the necrosis, preserved
5% and those with severe disease may develop end-stagethe glomerular endothelium and arterioles, and reduced the
renal failure [1]. In addition, as many as 20 to 40%number of apoptotic cells in glomeruli (at 4 hours) and in the
tubulointerstitium (at 4 days). The prosurvival effect of VEGF will develop chronic renal sequelae ranging from mild
for endothelium may relate in part to the ability of VEGF proteinuria to renal insufficiency and/or hypertension
to protect endothelial cells from factor-induced apoptosis, as
after 5 to 10 years [3–5]. The typical renal histologicaldemonstrated for tumor necrosis factor- (TNF-), which was
feature of HUS consists of intraluminal fibrin/plateletshown to be up-regulated through the course of this model
of renal microangiopathy. Endothelial nitric oxide synthase thrombi, often with fragmented red blood cells, swelling,
expression was preserved in VEGF-treated rats compared with and detachment of endothelial cells from the basement
its marked decrease in the surviving glomeruli and interstitium membrane, with subendothelial widening and occlusion
of the antibody-treated rats that did not receive VEGF.
of capillaries in glomeruli and intimal swelling and thick-Conclusions. VEGF protects against renal necrosis in this
ening in arterioles. All of these are thought to be second-model of thrombotic microangiopathy. This protection may be
mediated by maintaining endothelial nitric oxide production ary to primary endothelial injury [1, 2]. Patchy areas of
and/or preventing endothelial cell death. tubular injury and necrosis are observed as associated
findings. Histological factors correlating with poor clini-
cal outcome are the existence of cortical necrosis, exten-
sive glomerular involvement and arterial occlusive le-
sions [4].
1 Current address: Renal Section, Baylor College of Medicine, 6550 Insights into the pathogenesis and treatment of HUS
Fannin Street, Suite 1273, Houston, Texas 77030, USA. have been hampered by the lack of relevant animal mod-
els. Verotoxins do not induce HUS-like diseases in rodents,Key words: hemolytic uremic syndrome, apoptosis, tumor necrosis
factor-, nitric oxide synthase, arterial occlusive lesions, renal injury. due to the lack of the expression of globotriaosylceramide
(G3b), the receptor for verotoxins, on endothelial cells.Received for publication October 18, 2000
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body in rats [6]. Histologically and ultrastructurally, this versed-phase chromatography columns. The purified
product was lyophilized to dryness, resuspended in phos-model is characterized by renal microvascular injury with
platelet aggregation, fibrin deposition, glomerular and ar- phate-buffered saline (PBS), and stored at 80C until
use. Although the rhVEGF121 was fully active in an endo-teriolar endothelial swelling and detachment, accumula-
tion of electrolucent material in subendothelial spaces, thelial cell mitogenic assay, amino acid sequencing and
mass spectrometry indicated that the product was miss-and mesangiolysis. Tubular necrosis and interstitial dis-
ease are also observed. The ultrastructural and histologi- ing four amino acids on the N terminus of the molecule
and one amino acid from the C terminus. VEGF121 is thecal features of this model are similar to those of human
HUS [7]. only isoform of VEGF that lacks a heparin-binding region
[10]. We reasoned that it could be injected and circulateBecause the clinical and experimental forms of HUS
are primarily initiated by acute injury to endothelial cells, to an affected organ such as the kidney, and further that
it could be administered via subcutaneous injection, itswe have hypothesized that growth factors that promote
endothelial cell survival or angiogenesis may provide lack of binding to the extracellular matrix allowing it to
diffuse. This was proven by direct comparison of circulat-benefit. One of the most important endothelial growth
factors is vascular endothelial growth factor (VEGF) ing plasma levels of subcutaneously administered VEGF121
and its heparin-binding isoform, VEGF165 (Fig. 1).[8–11]. We have recently shown that the chronic adminis-
tration of VEGF in a non-necrotizing model of renal
Experimental protocolmicroangopathy induced by low-dose administration of
anti-GEN can stimulate angiogenesis and accelerate his- Twenty-one male Sprague-Dawley rats weighing 200
to 250 g were used. Experimental TMA was inducedtologic and functional recovery [12]. While this latter
study is of interest, it did not address whether VEGF by selective perfusion of the right kidney through the
superior mesenteric artery with 80 mg/kg purified IgGcan act as an endothelial cell survival factor because
VEGF treatment was initiated after maximal glomerular of goat anti-rat GEN antibody as previously described
[6]. The nonperfused left kidney was left in situ. Theinjury [6, 12] and in a model lacking an acute necrotic
component, which correlates with a poor clinical out- rats were divided into two groups, and 50 g/kg VEGF121
(N  17) or PBS (N  16) were subcutaneously injectedcome in HUS [4]. Recent in vitro evidence has suggested
an acute protective effect of VEGF on endothelial sur- one hour after anti-GEN antibody perfusion, followed
by twice-a-day injection at 12-hour intervals at differentvival [8, 9]. To determine whether VEGF exerts a sur-
vival effect on acutely injured renal microvasculature sites on the back for seven days. At four hours after
the perfusion, six rats in each group were sacrificed toin the absence of angiogenesis, we have modified the
experimental model by administering a larger dose of evaluate the presence of apoptosis in the kidney. For
the remaining rats, a small renal biopsy was performedanti-endothelial antibody eventuating in acute massive
renal infarction. In this model, VEGF was administered at 10 minutes and 4 days after the perfusion, and the
right kidney was removed at day 7.one hour after induction of injury, and the effects on
endothelial cell survival and renal necrosis were evalu-
Renal histological studies and morphometryated. The short observation time (up to 7 days) precluded
any effects of VEGF on new capillary formation [13]. Methyl Carnoy’s fixed tissue was processed and par-
affin embedded, and 4-m sections were stained withWe report that VEGF is a potent endothelial cell survival
factor in vivo. It is the first growth factor to be shown the periodic acid-Schiff reagent (PAS). An indirect im-
munoperoxidase method was used to identify the fol-to reduce renal cortical and medullary necrosis in a
model of thrombotic microangiopathy. lowing antigens as we reported [15]: endothelial cells
with RECA-1, a monoclonal IgG1 antibody specific for
endothelial cells (Harlan Bioproducts, Indianapolis, IN,
METHODS
USA); platelets with PL-1, a mouse monoclonal antibody
Preparation of rhVEGF121 to rat platelets (generously provided by W.W. Baker,
University of Groningen, Groningen, The Netherlands);To eliminate a glycosylation site in the recombinant
product, the complementary DNA sequence for VEGF121 -smooth muscle actin (-SMA) with 1A4, a mouse anti-
-SMA monoclonal IgG2a antibody (Sigma Chemical Co.,was altered at codon 75 to encode glutamine rather than
asparagine. The sequence was then placed under the St. Louis, MO, USA); and endothelial nitric oxide syn-
thase (eNOS; NOS III) with a mouse anti-eNOS mono-control of the AOX1 promoter [14] in a Pichia pastoris
host cell, and expression of recombinant VEGF121 was clonal IgG1 antibody (Transduction Labs, Lexington,
KY, USA), as previously described [16]. To confirm theinitiated in fermentation culture by the addition of meth-
anol. Conditioned medium from the fermentation was glomerular endothelial binding of the injected anti-GEN
IgG, immunofluorescence was performed on 4-m fro-filtered and then fractionated sequentially on ion ex-
change, hydrophobic interaction, metal affinity, and re- zen tissue sections from the 10-minute biopsies using
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rabbit anti-goat IgG (Cappel, Organ Teknika Corp., sham-operated controls. Data quoted are the mean of
Durham, NC, USA) [6]. triplicate analysis.
Morphometric analysis of the percentage of area occu-
Detection of apoptosis in vivopied by necrotic tissue, RECA-1–positive glomeruli den-
sity, -SMA positive vessels, and the percentage of area Apoptotic cells were detected by two well-established
occupied by eNOS-positive tissue was performed using methods. First, cells were identified as undergoing apo-
computer-assisted image analysis software (Optimas, ver- ptosis on PAS-stained sections when they exhibited
sion 6.2; Media Cybernetics, Silver Springs, MD, USA) marked chromatin condensation, which is a classic mor-
and digitized images. The percentage of area occupied phological hallmark of apoptosis [18, 19]. Second, the
by necrotic tissue was measured at 2.5 on whole cortex terminal deoxynucleotidyl transferase (TdT)-mediated
and medulla in sagittal sections of each biopsy. The com- dUTP-biotin nick end-labeling (TUNEL) assay was used
bination of the central and peripheral zone of necrosis to identify apoptosis in the kidney [18]. Briefly, formalin-
was evaluated. The number of RECA-1–positive glomer- fixed sections were deparafined and rehydrated, followed
uli, PL-1–positive glomeruli, and -SMA–positive vessels
by an antigen retrieval step involving boiling the tissueswas quantified per 5 field in the entire cortical and jux-
in citric acid (pH 6.0). Samples were then incubatedtamedullary regions of sagittal sections, and mean num-
with Proteinase K (6.2 g/mL; Boehringer Mannheim,ber per mm2 was calculated. The percentage of area oc-
Indianapolis, IN, USA), followed by the mixture of TdTcupied by eNOS-positive tissue was measured per 5
(300 U/mL; Amersham Pharmacia Biotech, Piscataway,field and the mean percentage of area was calculated. For
NJ, USA) and Bio-14-dATP (0.94 nmol/L; GIBCO BRL,tubulointerstitial eNOS evaluation, non-necrotic corti-
Grand Island, NY, USA). Biotinylated adenosine 5-cal and juxtamedullary regions excluding glomeruli were
triphosphate (ATP) was detected by the ABC stainingexamined. Semiquantification of glomerular eNOS im-
method (Vector Laboratories, Burlingame, CA, USA).munostaining was performed as previously described
Apoptosis of glomerular or tubulointerstitial cells was[17]. Briefly, staining was graded (0–5) based on the %
evaluated by counting the number of TUNEL-positiveof eNOS positive area per non-necrotic glomerulus as
glomerular cells in 50 sequentially selected glomeruli orfollows: 0, no staining present; grade 1, 10% eNOS
positive area; grade 2, 10 to 25% eNOS-positive area; TUNEL-positive tubulointerstitial cells in 20 sequen-
grade 3, 25 to 50% ; grade 4, 50 to 75%; and grade 5, tially selected nonoverlapping fields of renal cortex at
75 to 100%. 400 magnification, respectively, and expressed as the
number of positive cells per glomerulus or per high
Determination of renal TNF- mRNA levels power field (hpf) [20].
Total RNA was isolated from dissected renal cor-
tex in a separate group of rats at seven days after the Cell culture and induction of apoptosis
initiation of injury using the Qiagen RNeasy Mini Kit Human umbilical vein endothelial cells (HUVECS)
(Qiagen Inc., Valencia, CA, USA); 100 ng was subjected were placed in complete culture medium supplemented
to quantitative real-time PCR using an ABI Prism 7700 with 5% fetal bovine serum and allowed to grow to con-
Sequence Detection System (PE Applied Biosystems, fluence. Recombinant human TNF- (R&D Systems,
Foster City, CA, USA). The following primers and
Minneapolis, MN, USA) was added to the cultures for sixprobes for rat TNF- and 18S ribosomal RNA were de-
hours, at which point the cells were assayed for caspase-3signed using Primer Express software (PE Applied Bio-
activity, as an index of apoptosis [21, 22], using ApoAlertsystems): for TNF- forward 5-ACAAGGCTGCCC
Caspase-3 Detection Assay (Clontech, Palo Alto, CA,CGACTAT-3, reverse 5-CTCCTGGTATGATGGAA
USA). The effect of VEGF upon TNF-–induced caspaseATC-3, and probe 5-6FAM-TGCTCCTCACCCACAC
activity was ascertained by coincubating the HUVECSCGTCAGC-TAMRA-3; for 18S rRNA forward 5-CGG
with rhVEGF121 at concentrations of either 5 or 50 ng/CTACCACATCCAAGGAA-3, reverse 5-GCTGGA
mL, reflecting plasma levels attained by rhVEGF whenATTACCGCGGCT-3 and probe 5-6FAM-TGCTGG
administered subcutaneously.CACCAGACTTGCCCTC-TAMRA-3. Multiscribe re-
verse transcriptase and AmpliTaq Gold polymerase (PE
Applied Biosystems) were used in all RT-PCR reactions.
StatisticsRelative quantitation of 18S rRNA and rat TNF-
Values are expressed as mean 	 SE. Differences be-mRNA was calculated using the comparative threshold
tween the VEGF and vehicle-treated groups were evalu-cycle number for each sample fitted to a five point stan-
ated with the unpaired Student t test except comparisondard curve (ABI Prism 7700 User Bulletin #2; PE Ap-
of the number of apoptotic cells, which was performedplied Biosystems). TNF- mRNA levels were normal-
ized to 18S rRNA and related to samples derived from with Mann-Whitney U test.
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Fig. 1. Pharmacokinetics of VEGF121 (solid line)
and VEGF165 (dotted line) after subcutaneous
injection. The plasma levels of VEGF121 and
VEGF165 in six rats after subcutaneous injection
of 100 g is shown. The injection of VEGF121
resulted in significant plasma levels, peaking
100 minutes after injection.
RESULTS capsule was relatively preserved in some rats, tissue ne-
crosis was extensive throughout the cortex and medullaVEGF121 protects animal from renal necrosis in a
(Fig. 2C). In marked contrast, systemic administrationhemolytic uremic syndrome-like model
of VEGF121 for seven days after anti-GEN antibody per-The HUS-like model was induced in rats by selective fusion resulted in elimination of macroscopic evidence of
perfusion of the right renal artery with anti-GEN anti- cortical infarction (Fig. 2D) with preservation of renal
body [6] and the non-perfused left kidney was left in architecture apparent upon sectioning (Fig. 2E), except
situ. The lot and dose utilized (80 mg IgG/kg) induced for small patchy areas of necrosis in the medulla (Fig. 2F).
a much more severe form of thrombotic microangiopathy Necrotic areas in the control kidneys were widely
than that reported previously [6] and resulted in large distributed in the medulla and cortex. Light micro-
patchy areas of cortical and medullary necrosis. One scopic analysis revealed heterogeneous patches of necro-
hour after the injection of antibody, rats were random- sis (Fig. 3A, arrow), typically with a central zone com-
ized to receive either recombinant human VEGF121 or posed of necrotic tissue with nuclear loss in glomeruli
vehicle. VEGF121 was chosen because it is the only iso- and tubules (Fig. 3B), a peripheral zone with polymor-
form of VEGF that has no heparin-binding ability and, phonuclear cell infiltration, and a marginal zone with
therefore, can result in therapeutically effective plasma various degrees of necrosis, tubular regeneration, and
levels when administered subcutaneously (Fig. 1). The fibrosis (Fig. 3C). Sagittal sections revealed that approxi-
dose of VEGF121 used (50g/kg twice a day) was selected mately 50% of cortex and more than 80% of the medulla
as it has been found to be an effective dose for inducing had become necrotic by day 7. Between necrotic areas,
angiogenesis when administered subcutaneously in an marked atrophy or dilation of tubules, interstitial fibro-
animal ischemic hind-limb model. These plasma levels sis, and mononuclear cell infiltration were observed. In
of VEGF do not affect systemic blood pressure (R. Ter- contrast, the administration of VEGF beginning one
jung and J. Abraham, unpublished observations). hour after disease induction dramatically reduced the
At day 7, control rats perfused with anti-GEN anti- degree of necrosis. Quantification of the necrosis by com-
body developed severe renal disease with macroscopic puter image analysis demonstrated that 5 	 3% of the
evidence of infarction (Fig. 2A). The perfused kidney of cortex of VEGF-treated animals was necrotic compared
every animal in the control group was swollen and mot- to 46 	 10% in controls (P  0.01); similarly, VEGF-
tled, and the surface was covered with yellowish-white treated rats showed a more than 50% reduction in med-
areas. The sectioned surface of every kidney demon- ullary necrosis (81 	 19% in the controls versus 37 	
strated patchy yellowish-white areas distributed in the 11% in VEGF-treated rats, P  0.05; Fig. 3D). In con-
cortex as well as in the medulla consistent with infarction trast to massive necrosis of the kidney in TMA rats, the
most prominent histological feature in the kidneys of(Fig. 2B, C). Although cortical tissue just beneath the
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Fig. 2. Vascular endothelial growth factor (VEGF) reduces renal necrosis in a thrombotic microangiopathy (TMA) model. In control rats with
TMA lesions, the kidneys at day 7 were covered with yellowish-white areas of necrosis (A), which were distributed in both cortex and medulla
in sectioning (B). In some rats, the narrow rim of cortical tissue just underneath the capsule was relatively preserved but necrotic areas were
distributed extensively in the cortex and medulla (C ). In contrast, VEGF administration after anti-GEN antibody perfusion eliminated macroscopic
evidence of infarction on the surface (D), although some residual necrosis was evident in the medulla (E and F ).
VEGF-treated rats consisted of dilation and atrophy of genic goat IgG between two groups at 10 minutes after
perfusion (data not shown).tubules in the outer medulla and, to a lesser extent, in
the cortex (Fig. 3E).
VEGF121 administration preserves glomerularBy light microscopy, the viable glomeruli in control rats
endothelium and vasculaturedemonstrated endothelial injury, duplication of glomeru-
lar basement membrane with subendothelial widening We next evaluated the effects of VEGF on the glomer-
(Fig. 4A), and intravascular thromboses. Glomeruli from ular and arteriolar injury induced by anti-GEN antibody
VEGF-infused rats displayed a more normal architecture, using immunohistochemical analysis. The glomerular en-
with less cellular damage and thromboses (Fig. 4B). dothelial lining was examined by immunostaining with
RECA-1, a monoclonal antibody to an endothelial cell-There was no difference in deposition of the patho-
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Fig. 3. VEGF reduces cortical and medullary necrosis induced by anti-GEN antibody. Renal histology was examined at day 7 by periodic acid-
Schiff (PAS) staining. Perfusion of anti-GEN IgG resulted in massive cortical and medullary necrosis (A, 25). A central dead zone composed
of necrotic tissues with nuclear loss in glomeruli and tubules (B, 100), peripheral dead zone with polymorphonuclear cell infiltration (B, arrow),
and marginal zone with various degrees of necrosis, tubular regeneration and fibrosis (C,100) are also shown. Although there was tubulointerstitial
injury with tubular dilatation, interstitial widening, and patchy areas of necrosis particularly in the medulla, VEGF treatment caused dramatic
reduction in necrotic area in the cortex and medulla (D, 25, and E, 100).
Fig. 4. Renal injury is lessened by VEGF
treatment. (A) Glomerulus of control rat dem-
onstrating features of thrombotic microangio-
pathy, with endothelial swelling and detach-
ment, and duplication of glomerular basement
membrane with subendothelial widening (day 4,
600). (B) Glomerulus from a VEGF-treated
rat showing preservation of the glomerular
architecture, day 4 (600).
specific antigen [15]. At day 7, the number of glomeruli rats, P  0.05; Fig. 5A, B). In addition, the number of
glomeruli with platelet aggregation tended to be smallerwith intact endothelium in entire cortical and juxtamed-
ullary areas of sagittal sections was significantly greater in VEGF121-treated rats, although the difference was not
statistically significant (1.64 	 0.65 in the controls vs.in the VEGF121-treated group than in the control group
with anti-GEN antibody perfusion (3.3 	 1.3 per mm2 0.38 	 0.20 per mm2 in VEGF-treated rats, P 0.072).
The number of -SMA–positive vessels in sagittal sec-in the controls vs. 5.9 	 0.3 per mm2 in VEGF-treated
Suga et al: VEGF121 reduces renal infarction 1303
Fig. 5. VEGF preserves glomerular endo-
thelial lining and -smooth muscle actin
(-SMA)–positive arterioles. The glomerular
endothelial cells were stained with RECA-1, a
monoclonal antibody to endothelial cell-spe-
cific antigen. At day 7, the number of glomer-
uli with intact endothelial lining was signifi-
cantly greater in the VEGF-treated group (B,
100) than in the injured control group (A,
100). -SMA–positive vessels, characteristic
of arteries and arterioles, were rarely observed
in the medulla of controls (C, 25). In con-
trast, there was a preservation of interlobular
arteries, arterioles and vascular bundles (vasa
rectae) in VEGF-treated rats (D, 25). Some
-SMA–positive vessels were preserved in su-
perficial cortex of control rats (C, upper left),
but there was a significant decrease in the
number of -SMA–positive vessels, when
compared with VEGF-treated rats (D).
tions also was examined. -SMA–positive vessels, char- VEGF preserves eNOS expression
acteristic of arteries and arterioles, were rarely observed Endothelial nitric oxide synthase is normally expressed
in the medulla in control animals (Fig. 5C). However, in glomerular and peritubular capillary endothelial cells
preservation of interlobular arteries, arterioles, and vas- and in tubular epithelial cells of the outer medulla [16].
cular bundles (vasa rectae) was readily apparent in In control rats with severe TMA, eNOS expression was
VEGF-treated rats (Fig. 5D). Some -SMA–positive markedly diminished at day 7 with minimal expression
vessels were preserved in the superficial cortex of control in the endothelium of arteries, arterioles, and glomeruli
rats, but there was a significant decrease in the number of in the cortex and virtually no staining of eNOS in the
-SMA–positive vessels, when compared to the VEGF- medulla except capillary endothelial cells in the areas
treated group (10 	 1 in the controls vs. 15 	 2/mm2 in surrounding infarction (Fig. 6A, C). In VEGF-treated rats,
VEGF-treated rats, P  0.05). eNOS expression was preserved and remained widely dis-
The preservation of glomeruli with intact endothelium tributed in glomerular and vascular endothelial cells as
and -SMA–positive vessels suggested that VEGF might well as in vascular bundles and tubular epithelial cells
be acting as a survival factor for endothelial cells. VEGF in the medulla (Fig. 6B, D). Semiquantitative analysis
is known to exert at least two biological effects that could revealed that the intensity of glomerular eNOS staining
moderate vascular susceptibility to injury that would oth- was stronger in VEGF-treated rats than in controls in
erwise cause infarction of dependent tissue: (1) induction non-necrotic areas (1.2 	 0.2 in the controls vs. 2.0 	
and maintenance of eNOS expression and (2) inhibition 0.2 in VEGF-treated rats, P  0.05). Computer image
analysis in noninfarcted renal tissue also revealed betterof endothelial apoptosis.
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Fig. 6. VEGF treatment preserves endothe-
lial nitric oxide synthase (eNOS) expression in
rats with HUS-like lesions. In control rats, the
endothelial isoform of eNOS was markedly di-
minished with residual staining of the endothe-
lium of some arteries, arterioles, and glomeruli
in the cortex and with little staining in the
medulla except for occasional capillary endo-
thelial cells in the areas surrounding infarction
(marginal zone of infarction; A,50). In VEGF-
treated rats, eNOS was widely preserved in
glomerular and vascular endothelial cells as
well as in tubular epithelial cells and vascular
bundles in the medulla (B, 50). Glomerular
eNOS staining was stronger in VEGF-treated
rats than in controls in surviving non-necrotic
areas (C, controls 200; D, VEGF-treated
rats 200).
preservation of eNOS staining in tubulointerstitium did not reduce the number of apoptotic cells in the tubu-
lointerstitium at four hours, VEGF-infused rats did have(0.7 	 0.1 in the controls vs. 1.4 	 0.2 in VEGF-treated
rats, % of noninfarcted area, P  0.01). a threefold decrease in the number of TUNEL-positive
tubulointerstitial cells at day 4 (Fig. 7D).
VEGF121 as an endothelial survival factor To clarify the possible mechanisms by which VEGF
could reduce apoptosis, we examined the in vitro effect ofVascular endothelial growth factor can serve as an in
VEGF on endothelial apoptosis induced by TNF-, an in-vitro survival factor for vascular endothelium [8, 9]. We
flammatory cytokine known to be a potent inducer of en-therefore examined the effect of VEGF on apoptosis in
dothelial cell death. VEGF significantly protected HUVECour model. At four hours after the induction of the injury,
from TNF-–mediated apoptosis (Fig. 8). At 50 ng/mLsignificant numbers of apoptotic cells were observed within
of VEGF, a 100% inhibition of TNF-–induced caspasecapillary lumina of the glomeruli, consistent with the early
activation (a surrogate marker of apoptosis) in HUVECglomerular endothelial cell apoptosis that is observed in
was observed, in agreement with previous observationsthis model [20]. These intraluminal cells within glomeru-
[23]. Since HUVEC may differ from glomerular endo-lar capillaries showed typical nuclear chromatin conden-
thelial cells in several characters, the use of HUVECsation that is the morphological hallmark of apoptosis
must be regarded as a model system. Nonetheless, thisby PAS staining (Fig. 7A) as well as positive TUNEL
observation that VEGF reduced TNF-–mediated apo-staining (Fig. 7B). The administration of VEGF resulted
ptosis of cultured endothelial cells may be of relevancein a significant reduction of the number of TUNEL-
positive cells in glomeruli of TMA kidneys at four hours to the progression of renal necrosis in this model of HUS.
Quantitative real-time PCR analysis revealed a 8.4 	(Fig. 7C). Apoptosis of tubulointerstitial cells also was
prominent in rats with experimental TMA. While VEGF 1.2-fold increase in TNF- mRNA in control TMA rats
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Fig. 7. Glomerular and tubulointerstitial cell
apoptosis is markedly reduced in VEGF-treated
rats. Glomerular endothelial cell apoptosis
was demonstrated at four hours by PAS (A),
and terminal deoxynucleotidyl transferase
(TdT)-mediated dUTP-biotin nick end-label-
ing (TUNEL; B). Note the marked condensa-
tion of nuclear chromatin that is the classical
morphological marker of apoptosis. VEGF-
treatment protects glomerular cells (at 4 hours;
C ) and tubulointerstitial cells (at day 4; D)
from undergoing apoptosis in rat thrombotic
microangiopathy (TMA) kidney. Symbols are:
() vehicle; () VEGF; *P  0.05 vs. TMA
kidney treated with vehicle.
DISCUSSION
In the present study, severe renal injury was induced in
rats by the perfusion of an anti-endothelial cell antibody.
While the renal injury in this model is not initiated by
verotoxin-induced endothelial injury as in classical HUS,
the endothelial injury does result in features characteristic
of TMA, with platelet aggregation, fibrin deposition, and
glomerular and arteriolar endothelial injury. Indeed, the
dose of anti-endothelial cell antibody used in this study
resulted in a severe form, characterized by extensive glo-
merular involvement, arterial occlusive lesions and renal
necrosis, all histopathological features of severe HUS as-
sociated with a poor clinical outcome [4].
Fig. 8. VEGF inhibits TNF-–mediated apoptosis in HUVECS. Cas- Since endothelial cell injury induced by various insultspace-3 activity was determined as a measure of apoptosis in HUVECs
is regarded as a major pathogenic pathway of humanfollowing a six-hour stimulation with 1 ng/mL of TNF- with 0, 5, or
50 ng/mL of VEGF121. All experiments were performed in triplicate. HUS and TMA [2, 7], we hypothesized that the adminis-
tration of a growth factor, VEGF, which preferentially
targets the endothelium, might provide protection in this
at day 7 compared with sham controls. VEGF treatment model. At one hour after injection of the necrotizing
did not affect the level of TNF- mRNA expression antibody, VEGF121 administration was initiated, resulting
(6.6 	 0.4-fold increase), indicating its protective effects in reduced glomerular endothelial cell apoptosis, pre-
may be more related to the effector functions of TNF- served microvascular endothelium, and less cortical and
medullary necrosis.rather than modulation of its expression.
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The major beneficial effect of VEGF appeared to be VEGF in this model of renal disease. The lack of VEGF
therapeutic effect on expression of TNF in our modelthe reduction in cortical and medullary infarction. There
are likely multiple beneficial effects of VEGF that con- supports modulation of the effector functions of TNF
rather than modification of the induction of TNF as averge to prevent the progressive loss of vascular integrity
that underlies the consequent infarction of dependent mechanism for endothelial protection conferred by
VEGF. It is highly likely that there are numerous stimulirenal tissue. VEGF is known to stimulate endothelial NO
release as well as induce and maintain eNOS expression other than TNF contributing to endothelial cell death
in this complex in vivo model. The expression of TNFand activity [24, 25]. Local NO may then act to maintain
vascular patency by causing smooth muscle cell relax- associated with angiopathy and moderation of its impact
upon a model system of cultured endothelium shouldation and vasodilation and also by inhibiting platelet
adhesion and aggregation [26]. Indeed, VEGF induces be considered as a representative of potential multiple
protective effects conferred by VEGF in vivo, as shouldNO-dependent vasodilation in vivo [27], and VEGF-
induced NO release from microvascular endothelial cells the known inductive effects of VEGF on NO synthase
expression.inhibits leukocyte-endothelial interaction and preserves
vascular patency [28]. The observation in the present We have previously observed an initial increase in
glomerular VEGF expression in the earliest phases ofstudy that TMA rats displayed a marked loss of eNOS
expression, which was prevented by daily VEGF admin- this model of HUS, followed by a rapid decrease to
nearly undetectable levels within 48 hours after initiationistration, supports this as one of the potential mecha-
nisms for protection. of the lesion [6]. We speculate that the initial increase
in glomerular VEGF may comprise as an early renalVascular endothelial growth factor also is known to
be an endothelial cell survival factor [9, 23], inhibiting protective response to vascular injury, a response whose
attenuation could be associated with the subsequent pro-endothelial apoptosis induced in vitro by serum with-
drawal and irradiation. Apoptotic inhibition is consistent gression to endothelial injury and renal infarction. Thus,
administered VEGF could plausibly be considered anwith our finding that VEGF-treated rats had fewer intra-
luminal apoptotic cells in endothelial locations within exogenous amplification of an endogenous renal micro-
vascular defense mechanism that was inadequate to pro-glomeruli at four hours and better preservation of both
glomerular staining though the course of the injury. Be- tect against progressive vascular injury. It is important
to recognize, however, that protection by VEGF wascause there is no clear relevance of observations based
on in vitro serum withdrawal to in vivo observations on only partial, and identifying other ways to protect against
endothelial injury are needed.decreased endothelial cell death, we examined our model
for the presence of injurious factors that could induce Vascular endothelial growth factor also is a potent
angiogenic factor that can stimulate endothelial cell pro-apoptosis in endothelial cells. The inflammatory cytokine
TNF- has been shown to mediate apoptosis of cul- liferation and new capillary growth. However, the current
study was designed to evaluate the role of VEGF to pre-tured endothelial cells [23]. We demonstrated, to our
knowledge for the first time, that our model of HUS is vent necrosis as opposed to accelerating vascular re-
growth. Specifically, VEGF was administered before theassociated with a sustained increase in the expression of
mRNA for TNF-. We further demonstrated, as has maximal endothelial cell injury in order to determine
whether it could block endothelial apoptosis and renalbeen shown previously for another isoform of VEGF
[23], that VEGF121 is highly protective in vitro against infarction, and the major endpoints were preservation of
glomerular architecture and arteriolar structures, whichapoptosis induced in human umbilical vein endothelial
cells by TNF-, a protection observed at tissue culture are not products of acute angiogenesis. Furthermore,
capillary formation in response to VEGF usually takesconcentrations equivalent to plasma concentrations at-
tained in vivo after our injections of VEGF. Activation at least 10 to 14 days [13] and could not account for the
protection against infarction. However, we have recentlyof the anti-apoptotic phosphatidylinositol 3-kinase/Akt
signal transduction pathway by VEGF has been associ- studied the ability of chronic VEGF administration to
stimulate capillary repair in a milder noninfarction formated with endothelial survival in cultured endothelial
cells [29] and in a hind-limb ischemic model in vivo [30], of this model [12]. In this case, the VEGF was not initi-
ated until after 24 hours when endothelial injury wasas has elevation of Bcl-2 levels [31], induction of anti-
apoptotic proteins [32], and activation of cellular adhe- maximal, and then the VEGF was continued for 14 days
in order to give adequate time for capillary repair and an-sion [33]. It is beyond the scope of this article to ascribe
anti-apoptotic effects of VEGF in a complex model of giogenesis to occur. VEGF resulted in significant increases
in peritubular capillary density, less interstitial fibrosis,in vivo angiopathy and necrosis to any or all of these
mechanisms largely derived from in vitro observations. and better preservation of renal function [12]. Thus,
VEGF appears to benefit the diseased kidney in at leastHowever, they do support inhibition of apoptosis as a
plausible mechanism underlying the protective effects of two ways: preservation of the renal microvasculature
Suga et al: VEGF121 reduces renal infarction 1307
10. Ferrara N, Davis-Smyth T: The biology of vascular endothelialagainst acute injury and replacement, at least in the inter-
growth factor. Endocr Rev 18:4–25, 1997
stitium, of the microvasculature by stimulated new growth. 11. Tuder RM, Flook BE, Voelkel NF: Increased gene expression
In conclusion, the administration of exogenous VEGF for VEGF and the VEGF receptors KDR/Flk and Flt in lungs
exposed to acute or to chronic hypoxia: Modulation of gene expres-significantly reduced the severity of renal parenchymal
sion by nitric oxide. J Clin Invest 95:1798–1807, 1995infarction and necrosis in an experimental model of TMA 12. Kim YG, Suga SI, Kang DH, et al: Vascular endothelial growth
in rats. To our knowledge, this is the first demonstration of factor accelerates renal recovery in experimental thrombotic mi-
croangiopathy. Kidney Int 58:2390–2399, 2000in vivo infarct prevention by VEGF in any model of nec-
13. Couffinhal T, Silver M, Zheng LP, et al: Mouse model of angio-rotizing vascular injury, although VEGF has been shown genesis. Am J Pathol 152:1667–1679, 1998
to prevent sinusoidal damage in liver tissue subjected to 14. Cregg JM, Vedvick TS, Raschke WC: Recent advances in the
expression of foreign genes in Pichia pastoris. Biotechnology 11:cold preservation [33]. The observation that VEGF ad-
905–910, 1993ministration after the initiation of injury could reduce 15. Thomas SE, Anderson S, Gordon KL, et al: Tubulointerstitial
tissue necrosis in the kidney may be relevant to other dis- disease in aging: evidence for underlying peritubular capillary dam-
age, a potential role for renal ischemia. J Am Soc Nephrol 9:231–eases associated with cortical or renal infarction, such as
242, 1998eclampsia. Since intrarenal endothelial cell injury takes
16. Lombardi D, Gordon KL, Polinsky P, et al: Salt-sensitive hyper-
place in several forms of experimental glomerular dis- tension develops after short-term exposure to angiotensin II. Hy-
pertension 33:1013–1019, 1999eases, including the remnant kidney model and glomeru-
17. Hugo C, Pichler R, Gordon K, et al: The cytoskeletal linkinglonephritis [34, 35], where glomerular endothelial cells
proteins, moesin and radixin, are upregulated by platelet-derived
are not the primary sites of injury, prevention of endothe- growth factor, but not basic fibroblast growth factor in experimen-
tal mesangial proliferative glomerulonephritis. J Clin Invest 97:lial injury by VEGF also may be relevant to therapeutic
2499–2508, 1996intervention in various forms of glomerular disease.
18. Baker AJ, Mooney A, Hughes J, et al: Mesangial cell apoptosis:
The major mechanism for resolution of glomerular hypercellularity
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